Comment on: Safety of thiopurines in Inflammatory Bowel Diseases: Neither so good, nor so bad

Revista Española de Enfermedades Digestivas 2026

View at publisher
Authors: Francisca Carvajal, Rodrigo Quera, Gonzalo Pizarro, Christian von Mühlenbrock, Paulina Núñez F
DOI: 10.17235/reed.2026.11861/2026
Cited by: 0
References: 5

Abstract

In recent decades, the treatment of inflammatory bowel disease (IBD) has changed markedly. Several biological therapies and small molecules have been approved, leading to improved outcomes and quality of life of these patients. However, access to these new therapies is heterogeneous across different countries. In this scenario, the use of thiopurines, through personalized treatment, remain a valid option.

Fields of Study & Subjects

Inflammatory Bowel Disease Rheumatoid Arthritis Research and Therapies Pregnancy and Medication Impact

Publication details

Journal / source
Revista Española de Enfermedades Digestivas
Volume
118
Issue
10
Pages
597–599
Publication date
1 January 2026
Language
EN